http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20010032546-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-16 |
| filingDate | 1998-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2001-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20010032546-A |
| titleOfInvention | Novel compounds having cGMP-PDE inhibitory effect |
| abstract | The present invention is a novel condensed tetracyclic heterocyclic compound having a strong and highly selective inhibitory effect on cyclic GMP phosphodiesterase (hereinafter abbreviated as cGMP-PDE) and having high safety, and a method for producing them. Or a medicament comprising at least one thereof as an active ingredient, in particular pulmonary hypertension, ischemic heart disease, erectile dysfunction, female sexual dysfunction or a prophylactic and / or therapeutic agent for diseases in which cGMP-PDE inhibitory effect is effective, and a condensed tetracyclic system It relates to intermediates useful for preparing heterocyclic compounds. |
| priorityDate | 1997-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 727.